![Luke Walker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Luke Walker
Directeur/Membre du Conseil chez
ZENTALIS PHARMACEUTICALS, INC.
Fortune : 805 536 $ au 31/05/2026
Profil
Dr. Luke N.
Walker, MD, is a Chief Medical Officer at Umoja Biopharma, Inc., an Independent Director at Context Therapeutics, Inc. and an Independent Director at Zentalis Pharmaceuticals, Inc. He is on the Board of Directors at Context Therapeutics, Inc. and Zentalis Pharmaceuticals, Inc. Dr. Walker was previously employed as a Chief Medical Officer by Harpoon Therapeutics, Inc., a Vice President-Clinical Development by Seagen, Inc., and a Vice President-Clinical Development by CASCADIAN THERAPEUTICS INC.
He received his doctorate degree from the University of Oklahoma College of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/06/2026 | 201 384 ( 0,28 % ) | 805 536 $ | 31/05/2026 | |
| 24/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Luke Walker
| Sociétés | Poste | Début |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 29/05/2024 |
| CONTEXT THERAPEUTICS INC. | Directeur/Membre du Conseil | 04/09/2024 |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for treatment of cancer therapies | Directeur Technique/Scientifique/R&D | 01/01/2025 |
Anciens postes connus de Luke Walker
| Sociétés | Poste | Fin |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2024 |
| SEAGEN INC. | Corporate Officer/Principal | 01/10/2022 |
| CASCADIAN THERAPEUTICS INC (USA) | Directeur Technique/Scientifique/R&D | 09/03/2018 |
Formation de Luke Walker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
10
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Seagen, Inc.
 Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for treatment of cancer and immunologic diseases | Health Technology |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Develops therapeutic products for the treatment of cancer | Health Technology |
University of Oklahoma College of Medicine
 University of Oklahoma College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Zentalis Pharmaceuticals, Inc.
 Zentalis Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops clinical therapeutics for targeting fundamental cancer pathways | Health Technology |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for treatment of cancer therapies | Health Technology |
Context Therapeutics, Inc.
 Context Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company which develops treatment options for women living with hormone-dependent cancer | Health Technology |
